Table 2 Factors associated with the number of NMS in patients with PD.

From: Longitudinal evolution of non-motor symptoms in early Parkinson’s disease: a 3-year prospective cohort study

 

Unadjusted model

Adjusted model

B

95%CI

P-value

B

95%CI

P-value

Female sex

0.153

0.037–0.628

0.009*

0.416

0.110–1.571

0.196

Age

1.145

1.074–1.221

<0.001*

1.112

1.044–1.184

0.001*

Disease duration

1.573

1.007–2.458

0.047*

1.078

0.684–1.698

0.746

Education

0.971

0.818–1.154

0.741

1.045

0.891–1.225

0.588

LEDD

1.005

1.002–1.008

0.001*

1.002

0.998–1.006

0.360

Use of levodopa

10.912

1.768–67.357

0.010*

2.024

0.213–19.242

0.539

Use of dopamine receptor

1.636

0.275–9.755

0.589

0.421

0.066–2.676

0.359

Use of antidepressant

3.087

0.214–44.556

0.408

2.682

0.235–30.662

0.427

UPDRS III

1.172

1.097–1.251

<0.001*

1.124

1.053–1.201

<0.001*

  1. *Significant difference.
  2. NMS non-motor symptoms, PD parkinson’s disease, LEDD levodopa equivalent daily dose, UPDRS unified parkinson’s disease rating scale.
Back to article page